Literature DB >> 20888236

Drug-eluting stent for the treatment of symptomatic vertebral origin stenosis: Long-term results.

Xinpu Chen1, Qinghai Huang, Bo Hong, Yongwei Zhang, Yi Xu, Jianmin Liu.   

Abstract

Atherosclerotic stenosis originating from the vertebral artery (VA) is a well-known cause of stroke in the posterior circulation. Stent-assisted angioplasty using a bare metal stent is safe but used in a limited number of patients due to high rates of in-stent restenosis (ISR). A drug-eluting stent (DES) is an alternative for reducing ISR after stenting for atherosclerotic stenosis. We report the technical feasibility and mid to long-term clinical and angiographic outcomes after stenting with a DES in vertebral origin stenosis. This retrospective study included 47 consecutive patients treated with DES for vertebral origin stenosis. The demographics, indications for treatment, procedural technique, clinical and radiographical follow-up results were reviewed. The technical success rate was 100% without any complications. Postprocedure residual stenosis was 8.6% (range=0-12%). All patients were followed up clinically for a mean of 28.3 months (range=12-68 months), and two patients (4.2%) had recurrent stroke in stented-vessel territories at 5 and 17 months after the procedure, respectively. Digital subtraction angiography was performed at follow-up in 38 patients (80.9%) at a mean of 16.3 months (range=6-48 months) and showed two patients with ISR (5.3%) and four stent fractures (10.5%). One asymptomatic ISR was related to stent fracture. DES for vertebral origin stenosis are safe and effective with an acceptable lower ISR rate. However, stent fracture may be a potential complication and requires long-term follow-up. 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 20888236     DOI: 10.1016/j.jocn.2010.05.023

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  4 in total

1.  Drug eluting stents for symptomatic intracranial and vertebral artery stenosis.

Authors:  J D Fields; B D Petersen; H L Lutsep; G M Nesbit; K C Liu; A Dogan; D S Lee; W M Clark; S L Barnwell
Journal:  Interv Neuroradiol       Date:  2011-06-20       Impact factor: 1.610

2.  Validation and comparison of drug eluting stent to bare metal stent for restenosis rates following vertebral artery ostium stenting: A single-center real-world study.

Authors:  Long Li; Xu Wang; Bin Yang; Yabing Wang; Peng Gao; Yanfei Chen; Fengshui Zhu; Yan Ma; Haitao Chi; Xiao Zhang; Xuesong Bai; Yao Feng; Adam A Dmytriw; Tao Hong; Yang Hua; Liqun Jiao; Feng Ling
Journal:  Interv Neuroradiol       Date:  2020-08-16       Impact factor: 1.610

3.  Safety and Efficacy of Rapamycin-Eluting Vertebral Stents in Patients With Symptomatic Extracranial Vertebral Artery Stenosis.

Authors:  Gaoting Ma; Ligang Song; Ning Ma; Jie Shuai; Wei Wu; Jieqing Wan; Zhenwei Zhao; Guangjian Li; Sen Yin; Shenghao Ding; Jiang Li; Baixue Jia; Xu Tong; Dapeng Mo; Feng Gao; Xuan Sun; Yiming Deng; Xiaochuan Huo; Wei Li; Kangning Chen; Zhongrong Miao
Journal:  Front Neurol       Date:  2021-11-26       Impact factor: 4.003

4.  Outcomes of Endovascular Stenting in Symptomatic Vertebral Artery Ostial Stenosis.

Authors:  Roy El Koussa; Jaime Graft; Sarah Linder; Vibhav K Bansal
Journal:  Cureus       Date:  2022-01-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.